Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jessica Marcus

Nurse Practitioner, Family Princeton, WV Nurse Practitioner

NPI 1609427350 CMS profile 10723574

3997 Beckley Rd, Princeton, WV 24740

Open in the dashboard

General payments

$6,930

417 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Marcus of Princeton, WV is reported in the CMS Open Payments database as having received $6,930 across 417 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,567 88
2024 General $2,190 136
2023 General $2,558 156
2022 General $615 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Marcus
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jessica Marcus were reported at $1,567. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jessica Marcus Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $0 $124 $35–$379 $132
2022 $615 $141 $44–$430 $149
2023 $2,558 $154 $49–$476 $160
2024 $2,190 $165 $51–$504 $164
2025 $1,567 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $857 62 payments
  2. AstraZeneca Pharmaceuticals LP $838 39 payments
  3. AbbVie, Inc. $524 39 payments
  4. Pfizer Inc. $519 39 payments
  5. Lilly USA, LLC $513 28 payments
  6. Otsuka America Pharmaceutical, Inc. $456 23 payments
  7. Amgen Inc. $286 18 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $282 16 payments
  9. Abbott Laboratories $270 32 payments
  10. GlaxoSmithKline, LLC. $250 14 payments
  11. Other $2,135 107 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,833 416 payments
  2. Education $97 1 payment
Products named General payments · program years 2022–2025
  1. Ozempic $532 38 payments
  2. RYBELSUS $495 36 payments
  3. BREZTRI $489 19 payments
  4. FARXIGA $475 17 payments
  5. REXULTI $393 19 payments
  6. MOUNJARO $381 21 payments
  7. COMIRNATY $320 22 payments
  8. XIFAXAN $282 16 payments
  9. NURTEC ODT $274 21 payments
  10. AIRSUPRA $272 8 payments
  11. Other $5,476 345 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 131 drugs

Part D claims

7,381

Median for Nurse Practitioner: 389

Drug cost

$846,593

Median for Nurse Practitioner: $21,885

Branded share of claims

25.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 74 $89,425
Humira Pen Adalimumab Brand 13 $88,550
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 113 $86,773
Trulicity Dulaglutide Brand 51 $63,831
Farxiga Dapagliflozin Propanediol Brand 53 $55,469
Rybelsus Semaglutide Brand 25 $44,270
Linzess Linaclotide Brand 47 $40,627
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 60 $39,844
Tresiba Flextouch U-100 Insulin Degludec Brand 69 $33,787
Eliquis Apixaban Brand 38 $31,844

The 10 drugs with the highest cost, of 131 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$47,261

Of which drugs: $89

Medicare patients

148

Average age 71

Services billed

1,464

76 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 43%
Depression 33%
Diabetes 28%
Ischemic heart disease 24%
Chronic kidney disease 21%
COPD 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 78 $56
Injection, ceftriaxone sodium, per 250 mg J0696 Office 18 102 $30

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $141
  • Lundbeck LLC $16
$157 19 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $155
$155 53 —
MOUNJARO
  • Lilly USA, LLC $136
$136 16 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $133
$133 — —
JARDIANCE
  • Lilly USA, LLC $67
  • Boehringer Ingelheim Pharmaceuticals, Inc. $50
$117 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

417 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record